Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on VOLEX PLC. We currently have 11 research reports from 3 professional analysts.
|27Feb17 07:00||RNS||Trading Statement|
|21Feb17 09:52||RNS||Director/PDMR Shareholding|
|08Dec16 09:27||RNS||Director/PDMR Shareholding|
|28Nov16 07:00||RNS||Holding(s) in Company|
|11Nov16 07:00||RNS||Volex Plc: Half-year Report to 2 October 2016|
|17Oct16 07:00||RNS||Holding(s) in Company|
|26Jul16 12:30||RNS||Result of AGM|
Frequency of research reports
Research reports on
04 Apr 16
In Issue 2, we concluded that the VW emissions scandal was likely to result in faster development and adoption of hybrid and electric vehicles. In this issue, we discuss what we think will be a key megatrend of the 21st century: the strong push to decarbonise vehicles AND power generation. The implications for the Industrials sector are substantial and we attempt to identify some of the key winners and losers of what we think is now an unstoppable force. The full list starts on page 8 but key winners we identify are: Lithium, Copper, Hydrogen, Composites, batteries and fuel cells, electric motors, wind turbine components, solar cells, ac/dc convertors and all forms of power storage.
Forecast downgrade after interims
17 Nov 15
Recent interim results reflect tough trading with some key consumer electronic customers. With a focus on better margins and cash flow rather than chasing volume there is still a turnaround story to be had, albeit with mixed underlying markets, as the previous forecast recovery has been delayed. A better H2 is anticipated as some delayed customer programmes have now launched. We have reduced our forecasts for the current year, with a 17% cut in adjusted PBT. While disappointing, we continue to see a recovery/turnaround story.
30 Sep 15
Redcentric*: Interim trading update – on track (CORP) | iomart*: Interim trading update (CORP) | Corero Network Security*: Interims show progress (CORP) | Volex: Board changes and trading update (BUY) | Avingtrans^: Full-year results (BUY) | ZincOx Resources*: Interims show improved operational performance (CORP) | Proteome Sciences*: Interims in line (CORP) |Sphere Medical*: Model update (CORP) |ServicePower Technologies*: Interim results (CORP) |Litebulb*: Interim results (CORP) |Camco Clean Energy*: Roll-in of REDT minorities (CORP) |Zambeef*: Trading good but local FX collapse (CORP) |San Leon Energy*: Interim results and Moroccan well update (CORP) |Independent Oil & Gas*: Interim results (CORP)
N+1 Singer - T. Clarke - Strong conclusion to FY16, record order book
28 Mar 17
After significant upgrades at the time of the full year update (PBT forecast +43% FY16; +14% FY17), today’s results are c.4% ahead of our expectations at the PBT level and show strong growth on the prior year (PBT +48%). All regions achieved positive growth in revenue. The outlook statement refers to a still growing order book (£350m at the end of February vs. £330m at the year end) and the strength of recent trading, with London & the South East and Scotland said to be particularly positive. The Group has reiterated its ambitions to improve margins, but we have not incorporated this into our forecasts at this stage. We have nudged up our FY’17 forecasts (PBT +5%) and introduced FY’18 forecasts that imply 2% PBT growth. Despite the well justified bounce in the share price, the shares still trade at a significant discount to the peer group (7.6x FY17 PE, 4% yield).
Panmure Morning Note 29-03-2017
29 Mar 17
We are cutting our recommendation to HOLD as we see little upside from current levels given the lack of positive surprises in today’s trading update. Multiples of 4.4x 2017 sales and 17x 2017 EBITDA imply an expectation of at least slightly exceeding expectations. We had assumed that acquisitions will provide the momentum until organic investments deliver. However, acquisitions are proving elusive and excess cash is diluting returns. Moreover, our forecast relies on at least one order in vehicle simulator market, which has yet to be announced. The management has shown that it can use the financial markets to raise equity but it now needs to show that it can deploy excess equity productively.
N+1 Singer - Severfield - Strong H2 drives upgrades; CEO temporarily steps down due to ill health
28 Mar 17
Severfield’s trading update highlights that trading during H2 was strong and the Group now expects results to be ahead of expectations. Cash flow performance has been similarly strong with net funds at the year end also expected to be ahead of expectations. The strong performance was driven by both a better than expected revenue performance and better than expected growth in the operating margin. We expect to increase our FY16 PBT forecasts by c.9% to around £19.5m. In addition, we are disappointed to see that Ian Lawson (CEO) has taken a temporary leave of absence due to physical ill health. John Dodds (non-executive Chairman) will step up to Executive Chairman on an interim basis and Alan Dunsmore (FD) has agreed to assume the role of CEO on a similar basis. This should ensure the continuity of the business whilst Ian is recovering. The outlook for Sevefield remains positive and the Group has reiterated its medium term target to double PBT from £13.2m in FY16 by FY20. We remain positive on Severfield (one of our best ideas for 2017) and continue to see clear potential for it to outperform its medium term targets.
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)